Wei Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Jin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dandan Hu
University of Science and Technology of China 1 Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC Hefei, China
14 shared publications - Hu Liu
Shenzhen Third People’s Hospital 6 Department of Medical Oncology Shenzhen, China
14 shared publications - Jing Pan
University of Science and Technology of China 1 Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC Hefei, China
14 shared publications - Lin Lin
University of Science and Technology of China 1 Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC Hefei, China
14 shared publications - Lin Wang
Shenzhen Wondercel Biotechnology Limited, Shenzhen, China
14 shared publications - Ling He
Shenzhen Wondercel Biotechnology Limited, Shenzhen, China
14 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Purpose:This phase I clinical trial aims to evaluate the safety, expansion kinetics, and preliminary efficacy of nonarmored, nanobody-derived guanylyl cyclase 2C (GCC)–targeted chimeric antigen receptor (CAR) T cells in patients with heavily pretreated metastatic colorectal cancer. Patients and Methods:In this single-arm, open-label, phase I clinical trial, 24 patients who received at least 2 prior lines of treatment received GCC-targeted CAR T cells across 4 dose levels: 0.5 × 105, 1 × 106, 2 × 106, and 3 × 106 CAR T cells/kg. The primary endpoint was safety; secondary endpoints included antitumor activity and pharmacokinetics. Results:All patients experienced grade 3 or higher hematologic toxicity, and 75% developed cytokine release syndrome, both of which were generally manageable. Two treatment-related deaths occurred: 1 due to immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome and 1 due to intestinal fistula following rapid tumor regression in a lesion adherent to the intestinal wall. The objective response rate and disease control rate reached 33% and 63%, respectively. Eight patients achieved a partial response as their best response, 7 maintained stable disease, and 5 had progressive disease. Median progression-free survival was 57 days, and median overall survival was 190 days. Higher in vivo CAR T-cell expansion was associated with better disease control. Proof-of-concept activity was demonstrated, although response durability was limited and toxicity remains challenging. Conclusions:GCC-targeted CAR T cells demonstrated encouraging antitumor activity in heavily pretreated patients with colorectal cancer, with the initial data supporting GCC as a clinically actionable target. Further development will require dose selection, patient eligibility, and toxicity management optimization to improve the therapeutic profile.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Purpose:This phase I clinical trial aims to evaluate the safety, expansion kinetics, and preliminary efficacy of nonarmored, nanobody-derived guanylyl cyclase 2C (GCC)–targeted chimeric antigen receptor (CAR) T cells in patients with heavily pretreated metastatic colorectal cancer. Patients and Methods:In this single-arm, open-label, phase I clinical trial, 24 patients who received at least 2 prior lines of treatment received GCC-targeted CAR T cells across 4 dose levels: 0.5 × 105, 1 × 106, 2 × 106, and 3 × 106 CAR T cells/kg. The primary endpoint was safety; secondary endpoints included antitumor activity and pharmacokinetics. Results:All patients experienced grade 3 or higher hematologic toxicity, and 75% developed cytokine release syndrome, both of which were generally manageable. Two treatment-related deaths occurred: 1 due to immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome and 1 due to intestinal fistula following rapid tumor regression in a lesion adherent to the intestinal wall. The objective response rate and disease control rate reached 33% and 63%, respectively. Eight patients achieved a partial response as their best response, 7 maintained stable disease, and 5 had progressive disease. Median progression-free survival was 57 days, and median overall survival was 190 days. Higher in vivo CAR T-cell expansion was associated with better disease control. Proof-of-concept activity was demonstrated, although response durability was limited and toxicity remains challenging. Conclusions:GCC-targeted CAR T cells demonstrated encouraging antitumor activity in heavily pretreated patients with colorectal cancer, with the initial data supporting GCC as a clinically actionable target. Further development will require dose selection, patient eligibility, and toxicity management optimization to improve the therapeutic profile.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Immunohistochemical staining of GCC in tumor tissue for patient recruitment.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Immunohistochemical staining of GCC in tumor tissue for patient recruitment.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
GCC CAR-T cells have superior anti-tumor effects in vitro and in xenograft models of T84 tumor cells.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
GCC CAR-T cells have superior anti-tumor effects in vitro and in xenograft models of T84 tumor cells.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Cytokine release after GCC-CAR-T treatment
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Cytokine release after GCC-CAR-T treatment
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
IHC staining of GCC in normal human tissue.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
IHC staining of GCC in normal human tissue.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Representative images of the response of an umbilicus tumor lesion to GCC-CAR-T treatment.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Representative images of the response of an umbilicus tumor lesion to GCC-CAR-T treatment.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
QPCR-based assessment of the GCC DNA copy number in the 24 patients following GCC CAR-T cell therapy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
QPCR-based assessment of the GCC DNA copy number in the 24 patients following GCC CAR-T cell therapy.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Patient baseline, treatment, and response characteristics
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Patient baseline, treatment, and response characteristics
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tab. S4. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Association between IHC staining intensity and clinical response (Four patients were inevaluable for treatment response).
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tab. S4. from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Association between IHC staining intensity and clinical response (Four patients were inevaluable for treatment response).
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Safety and antitumor activity by dose level
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer
Safety and antitumor activity by dose level